Poly Adenosine Diphosphate Ribose Polymerase Market – Size, Share, Outlook, and Forecast till 2026

Worldwide Market Reports added Latest Research Report titled “Poly Adenosine Diphosphate Ribose Polymerase Market – Size, Share, Outlook, and Forecast till 2026”

Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfers them to the target proteins. This helps in restoring the damaged DNA. Various factors such as exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment can cause damage to DNA. PARP inhibitors helps in blocking the enzyme that is important for the repair of single stranded breaks in DNA. The cells, especially cancer cells are destroyed on inhibition of the DNA repair enzyme.

These inhibitors play an effective maintenance role in current cancer-combating strategies, as it has superior effect when compared to the existing ovarian cancer treatment. Drugs such as Talazoparib and Veliparib that will be useful for the treatment of ovarian cancer are in phase III clinical trials. Increasing number of research and development activities is a key trend in this market.

Request Sample of Copy of the Business Report: https://www.worldwidemarketreports.com/sample/196110

Increasing geriatric population, rising prevalence of cancer, rising health expenditures and improving economic conditions, and vast unmet medical needs are some of the major factors that are expected to drive growth of poly adenosine diphosphate ribose polymerase market over the forecast period. A combination of PARP and immuno therapy, increasing awareness among people, and development of biomarkers are key trends in this market.

However, side effects, resistance to PARP inhibitors, and regulatory challenges are some of the factors that might hamper growth of poly adenosine diphosphate ribose polymerase market.

Key Developments in Poly Adenosine Diphosphate Ribose Polymerase Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the poly adenosine diphosphate ribose polymerase market. On April 6, 2018, Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

On May 6, 2018, TESARO, Inc., an oncology-focused biopharmaceutical company, announced that it entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (niraparib) in patients with platinum-sensitive ovarian cancer.

Some of the major players operating in the poly adenosine diphosphate ribose polymerase market include Tesaro Inc., Clovis Oncology, AstraZeneca, and Abbvie Inc.


** If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domainsv and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,


Seattle, WA 98154,


Tel: +1 415 871 0703 

Show full profile

Basic Member

Reset Password